PMID- 35379929
OWN - NLM
STAT- MEDLINE
DCOM- 20230127
LR  - 20230219
IS  - 1530-0447 (Electronic)
IS  - 0031-3998 (Linking)
VI  - 93
IP  - 1
DP  - 2023 Jan
TI  - Pediatric inflammatory bowel disease: Fecal calprotectin response to Anti-tumor 
      necrosis factor alpha.
PG  - 131-136
LID - 10.1038/s41390-022-02045-4 [doi]
AB  - BACKGROUND: Fecal calprotectin (FC) is a marker of mucosal inflammation in 
      inflammatory bowel disease (IBD). We aimed to assess the effect of anti-tumor 
      necrosis factor alpha (TNFalpha) therapy on FC levels in children with IBD. METHODS: 
      The medical records of pediatric patients treated with anti-TNFalpha agents 
      (2015-2020) were reviewed retrospectively. 63 patients had FC levels measured 
      prior to anti TNFalpha induction with sequential measurements during follow-up. The 
      main outcome measures were time to FC response according to cutoffs of 250, 150, 
      100 and 50 microgr/gr. RESULTS: Mean age was 13.6 +/- 3 years [females 28 (44.4%), 
      Crohn's 55 (87%)]. Outcomes of < 250, < 150, < 100 and < 50 microgr/gr were achieved 
      by 52 (82%), 51 (81%), 44 (70%) and 32 (50%), respectively. The median time for 
      achieving these cutoffs was 4.8 (1.8-15.6), 7.9 (2.6-16.4), 10.0 (3.5-20.5) and 
      18.5 (7.0-64.7) months, respectively. Shorter time from diagnosis to treatment 
      was associated with achievement of FC < 50 microgr/gr (p = 0.03). There was no 
      association between age, disease type, anti-TNFalpha type, inflammatory markers, 
      disease activity indices at baseline and induction anti-TNFalpha trough concentration 
      and FC response. CONCLUSIONS: FC response was achieved by the majority of 
      patients treated with anti-TNFalpha within a short period of time. FC normalization 
      in responders required almost one year. IMPACT: Fecal calprotectin response was 
      achieved by the majority of pediatric patients within a relatively short period 
      of time after anti-TNFalpha induction and maintenance therapy. Fecal calprotectin 
      normalization required an average period of approximately one year in responders. 
      The faster response of fecal calprotectin is associated with shorter time from 
      diagnosis to anti-TNFalpha treatment. Inflammatory bowel disease treating physicians 
      should be aware of the relatively prolonged time to fecal calprotectin 
      normalization and to allow enough time for anti-TNFalpha therapy to express its full 
      potential prior to significant interventions.
CI  - (c) 2022. The Author(s), under exclusive licence to the International Pediatric 
      Research Foundation, Inc.
FAU - Matar, Manar
AU  - Matar M
AD  - The institute of Gastroenterology, Nutrition and Liver diseases, Schneider 
      Children's Hospital, Petach-Tikva, Israel. manarmatar@gmail.com.
FAU - Levi, Rachel
AU  - Levi R
AD  - The institute of Gastroenterology, Nutrition and Liver diseases, Schneider 
      Children's Hospital, Petach-Tikva, Israel.
FAU - Zvuloni, Maya
AU  - Zvuloni M
AD  - The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Shamir, Raanan
AU  - Shamir R
AD  - The institute of Gastroenterology, Nutrition and Liver diseases, Schneider 
      Children's Hospital, Petach-Tikva, Israel.
AD  - The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Assa, Amit
AU  - Assa A
AD  - The institute of Gastroenterology, Nutrition and Liver diseases, Schneider 
      Children's Hospital, Petach-Tikva, Israel.
AD  - The Juliet Keidan institute of Pediatric Gastroenterology and Nutrition, Shaare 
      Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, 
      Jerusalem, Israel.
LA  - eng
PT  - Journal Article
DEP - 20220404
PL  - United States
TA  - Pediatr Res
JT  - Pediatric research
JID - 0100714
RN  - 0 (Leukocyte L1 Antigen Complex)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Female
MH  - Humans
MH  - Child
MH  - Adolescent
MH  - Retrospective Studies
MH  - Leukocyte L1 Antigen Complex
MH  - *Inflammatory Bowel Diseases/diagnosis/drug therapy
MH  - *Crohn Disease/diagnosis
MH  - Tumor Necrosis Factor-alpha
MH  - Necrosis
MH  - Feces
MH  - Biomarkers
EDAT- 2022/04/06 06:00
MHDA- 2023/01/28 06:00
CRDT- 2022/04/05 05:32
PHST- 2021/08/24 00:00 [received]
PHST- 2022/03/06 00:00 [accepted]
PHST- 2021/12/19 00:00 [revised]
PHST- 2022/04/06 06:00 [pubmed]
PHST- 2023/01/28 06:00 [medline]
PHST- 2022/04/05 05:32 [entrez]
AID - 10.1038/s41390-022-02045-4 [pii]
AID - 10.1038/s41390-022-02045-4 [doi]
PST - ppublish
SO  - Pediatr Res. 2023 Jan;93(1):131-136. doi: 10.1038/s41390-022-02045-4. Epub 2022 
      Apr 4.